이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

어린이의 AgRP 및 GH/IGF-1 축

2026년 9월 22일 업데이트: Pamela U. Freda, Columbia University

아구티 관련 펩타이드(AgRP)와 어린이의 GH/IGF-1 축

Recent data support the existence of a GH-Agouti-related peptide (AgRP) axis. The neuropeptide AgRP promotes food intake and has important effects on energy homeostasis. Recent evidence suggest that GH stimulates AgRP and AgRP may mediate some of GH's important nutritional and metabolic effects. main goals of this project are to characterize, for the first time, plasma levels of AgRP in children and to determine how these relate to GH and IGF-1 levels, age, body composition, clinical and other endocrine parameters. To accomplish this, we will conduct two studies, one being a cross-sectional study that will measure AgRP levels in 140 healthy children ages 5-17 and the second being a prospective study that will measure the change in plasma AgRP levels in response to GH treatment in 16 children who receive this as part of their clinical care for GH deficiency or short stature.

연구 개요

상태

아직 모집하지 않음

상세 설명

Protocol 1 This will be a cross-sectional study in 140 healthy children. Participation will include one visit that will take place between 8-9 am and after a fast from midnight the night before.

Procedures at the visit will include:

  1. Review of medical history
  2. Anthropometrics measurements: Weight, height, waist and hip circumferences.
  3. Collection of information from medical record including growth records and physical examination findings including features relevant to pubertal stage in all children and onset of menses in females.
  4. Assessment of pubertal status and Tanner stage based on physical examination.
  5. Collection of information on diet, activity level and sleep.
  6. Blood Sampling: venous blood will be sampled from a peripheral vein for measurement of AgRP, GH, IGF-1, leptin, SOb-R, triglycerides, insulin, glucose, testosterone(males), estradiol(females), DHEAS and cortisol levels. Insulin and glucose levels will be used to assess insulin resistance by HOMA & QUICKI.

Protocol 2 This will be a prospective study in 16 children who will be studied before and at 4 time points (1 week, 2 weeks, 1 month and 2 months) after starting GH treatment as part of their clinical care. This protocol will study subjects Groups 2 and 3. Growth hormone will not be prescribed as part of this study. Children will be treated clinically with GH as prescribed by their Pediatric Endocrinologist for FDA approved indications and according to standard guidelines for dosing for treatment of GH deficiency in children.

Each visit that will take place between 8-9 am and after a fast from midnight the night before.

Procedures at each visit will include:

  1. Review of medical history
  2. Anthropometrics measurements: Weight, height, waist and hip circumferences, skinfold thicknesses.
  3. Collection of information from medical record including growth records and physical examination findings including features relevant to pubertal stage in all children and onset of menses in females. GH dose and compliance will be recorded at follow up visits.
  4. Collection of information on diet, activity level and sleep.
  5. Blood Sampling: Venous blood will be sampled at a peripheral vein for:

Baseline (pre-GH treatment): measurement of AgRP, GH, IGF-1, IGFBP-3, leptin, SOb-R, triglycerides, insulin and glucose, testosterone(males), estradiol(females), DHEAS and cortisol levels.

Follow up visits on growth hormone: measurement of AgRP, IGF-1, IGFBP-3, leptin, SOb-R, triglycerides, insulin, glucose and cortisol levels.

Insulin and glucose levels will be used to assess insulin resistance by HOMA & QUICKI.

연구 유형

관찰

등록 (추정된)

156

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

5년 (어린이)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Healthy children: 140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center.Children will be recruited from among the healthy children visiting primary care Pediatricians at our medical center.

GH deficient and idiopathic short stature children: 16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature. They will be representative of the diverse racial and ethnic mix of our hospital's patient population.

설명

Healthy children

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-17 years
  2. Normal weight at birth
  3. Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.

Exclusion Criteria:

  1. Genetic defects, chronic illnesses.
  2. Current prescription medication use
  3. Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry.

Children with GH deficiency:

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-9 years who are prepubertal
  2. Normal weight at birth
  3. Growth failure
  4. Peak GH response to 2 GH stimulation tests < 10 ng/ml
  5. Normal renal and liver function

Exclusion criteria:

  1. Multiple pituitary hormone deficiencies,
  2. GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
  3. History of diabetes or malignancy
  4. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.

Children with idiopathic Short Stature:

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-9 years who are prepubertal
  2. Normal weight at birth
  3. Height >2.25 SD below mean for age
  4. Peak GH response to 2 stimulation tests >10 ng/ml or normal IGF-1 and IGFBP-3 levels
  5. No prior supplemental growth hormone exposure
  6. Normal renal and liver function

Exclusion criteria:

  1. Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
  2. History of diabetes or malignancy
  3. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: CROSS_SECTIONAL

코호트 및 개입

그룹/코호트
Group 1: Healthy children

140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center.

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-17 years
  2. Normal weight at birth
  3. Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.

Exclusion Criteria:

  1. Genetic defects, chronic illnesses.
  2. Current prescription medication use
  3. Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry.
Group 2: Children with GH deficiency

16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature.

They will be representative of the diverse racial and ethnic mix of our hospital's patient population.

GH deficiency:

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-9 years who are prepubertal
  2. Normal weight at birth
  3. Growth failure
  4. Peak GH response to 2 GH stimulation tests < 10 ng/ml
  5. Normal renal and liver function

Exclusion criteria:

  1. Multiple pituitary hormone deficiencies,
  2. GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
  3. History of diabetes or malignancy
  4. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.
Group 3: Children with short stature

Idiopathic Short Stature:

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-9 years who are prepubertal
  2. Normal weight at birth
  3. Height >2.25 SD below mean for age
  4. Peak GH response to 2 stimulation tests >10 ng/ml or normal IGF-1 and IGFBP-3 levels
  5. No prior supplemental growth hormone exposure
  6. Normal renal and liver function

Exclusion criteria:

  1. Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
  2. History of diabetes or malignancy
  3. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Protocol 1: Correlation of Plasma AgRP levels with IGF-1 levels
기간: Baseline (cross-sectional at single time point, no intervention)

Plasma AgRP levels correlation with IGF-1 levels Protocol 1: Correlation of Plasma AgRP levels with IGF-1 levels

Baseline (cross-sectional at single time point, no intervention)
Protocol 2: Change in plasma AgRP levels with GH therapy
기간: baseline to 2 months

Change in plasma AgRP levels from pre-GH therapy to post-GH therapy

baseline to 2 months

2차 결과 측정

결과 측정
측정값 설명
기간
Protocol 1: Correlation of plasma AgRP levels with age
기간: Baseline (cross-sectional testing at one time point, no intervention)

Correlation of plasma AgRP levels with age

Baseline (cross-sectional testing at one time point, no intervention)
Protocol 1: Correlation of plasma AgRP levels with leptin levels
기간: Baseline (cross-sectional testing at one time point, no intervention)

Correlation of plasma AgRP levels with leptin levels

Baseline (cross-sectional testing at one time point, no intervention)
Protocol 1: Correlation of plasma AgRP with percent body fat (determined from skinfold thickness)
기간: Baseline (cross-sectional testing at one time point, no intervention)

Correlation of plasma AgRP with percent body fat (determined from skinfold thickness)

Baseline (cross-sectional testing at one time point, no intervention)
Protocol 2: Change in AgRP levels correlation with change in IGF-1 levels
기간: Baseline to 2 months

Correlation of change in AgRP levels with change in IGF-1 levels from baseline to 2 months of GH therapy

Baseline to 2 months
Protocol 2: Change in AgRP level correlation with pre-treatment leptin levels
기간: Baseline to 2 months

Correlation of change in AgRP level from baseline to 2 months of GH therapy with pre-treatment leptin levels

Baseline to 2 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 6월 10일

기본 완료 (추정된)

2027년 12월 31일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2022년 11월 30일

QC 기준을 충족하는 최초 제출

2022년 12월 8일

처음 게시됨 (실제)

2022년 12월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 22일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다